Tenax Therapeutics (TENX) investor relations material

Company overview and business model

• Focuses on developing novel cardiopulmonary therapies using a clinician-driven approach led by key opinion leaders and heart failure experts.

• Prioritizes Phase 3 clinical trials for levosimendan in pulmonary hypertension and has deprioritized imatinib for now.

• Levosimendan and imatinib have established safety profiles from global use in other indications for over 20 years.

• Plans to submit marketing authorization applications after completion of Phase 3 trials.

• Operates as a smaller reporting company, utilizing scaled disclosure and reporting requirements.

Financial performance and metrics

• Raised $25 million in a private placement in March 2025 and approximately $100 million in August 2024.

• Proceeds are allocated to advancing Phase 3 clinical programs.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical trials, manufacturing, commercialization, working capital, and capital expenditures.

• Management retains broad discretion over allocation of net proceeds.

• Proceeds may be temporarily invested in capital preservation instruments.